Topical IOP-lowering drugs

Phase 3Small molecule

Topical IOP-lowering drugs is one of 6 small molecule programs targeting Neovascular Glaucoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neovascular GlaucomaActive, not recruiting

Neovascular GlaucomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Neovascular Glaucoma

#DrugCompanyPhaseTrials

Eylea

Regeneron

Phase 3

6 2

Intravitreal Ranibizumab

Roche

Approved

2 3

Lucentis

Roche

Phase 3

2 4

Topical IOP-lowering drugs

Bayer

Phase 3

1 5

Travatan

Novartis

Preclinical

1 6

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neovascular Glaucoma1 trial

Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied

Completed· Bayer logo

Bayer·Phase 3·NCT03639675·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Topical IOP-lowering drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Topical IOP-lowering drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Topical IOP-lowering drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Topical IOP-lowering drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neovascular Glaucoma1 trial

References

Drug Info

Quick Facts

Related News